Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing small molecule therapeutics targeting cancers. The company's lead programs consist of ZN-c5, an oral selective estrogen receptor degrader for estrogen-receptor-positive, HER2-negative breast cancer which is in clinical stage. It operates principally in New York and San Diego. Zentalis Pharmaceuticals, Inc. is based in NEW YORK.
| Revenue (Most Recent Fiscal Year) | $67.43M |
| Net Income (Most Recent Fiscal Year) | $-165.84M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.30 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -245.74% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -65.48% |
| Return on Assets (Trailing 12 Months) | -51.05% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.94 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.94 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.11 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.67 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.33 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.13 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 71.95M |
| Free Float | 70.58M |
| Market Capitalization | $89.94M |
| Average Volume (Last 20 Days) | 0.66M |
| Beta (Past 60 Months) | 1.81 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.90% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |